Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Pheon launches for antibody-drug conjugates to treat cancer

by Gina Vitale
October 1, 2022 | A version of this story appeared in Volume 100, Issue 35

 

Pheon Therapeutics has launched with $68 million in financing to develop antibody-drug conjugates (ADCs) for solid tumors. Its lead program, for which it expects to submit an investigational new drug application to the US Food and Drug Administration within 18 months, “exploits a novel target that is highly expressed in a broad range of solid tumors,” the company says. Pheon plans to disclose the target early next year, CEO Bertrand Damour says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.